FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155025544> ?p ?o ?g. }

• W3155025544 abstract "Abstract Background Chemosensitivity testing, including collagen gel droplet-embedded culture drug sensitivity test, has proven to be a useful tool in therapeutic decision-making. This retrospective analysis investigated chemosensitivity testing of peritoneal metastases collected during cytoreductive surgery (CRS), and its impact on survival in patients with colorectal cancer. Methods All patients with peritoneal metastasis from colorectal cancer who underwent CRS with or without hyperthermic intraperitoneal chemotherapy (HIPEC) between November 2008 and October 2014 were included. The growth inhibition rate was expressed as the ratio between the image density after treatment (T) and that before treatment (control, C). Tumours with a reduction in T/C ratio of less than 20 per cent were defined as resistant and those with a reduction of 20 per cent or more as sensitive. Groups were compared for overall (OS) and disease-free (DFS) survival. Results Of 84 eligible patients, 81 received neoadjuvant chemotherapy (NACT), including 56 patients with an oxaliplatin-based regimen. Mean(s.d.) follow-up was 23·4(22·9) months. The median overall survival of all patients was 19·0 (i.q.r. 5·7–36·1) months, with a progression-free survival time of 10·1 (4·5–17·0) months. Patients who received oxaliplatin-based NACT had significantly altered chemosensitivity to oxaliplatin; only 20 of 51 such patients showed chemosensitivity to oxaliplatin compared with 16 of 24 who did not undergo oxaliplatin-based NACT (P = 0·046). However, patients who showed chemoresistance to oxaliplatin had similar OS to those with chemosensitivity (18·8 versus 18·1 months; P = 0·835). The choice of HIPEC agents in patients who received oxaliplatin-based NACT did not significantly influence survival (oxaliplatin versus mitomycin C: median OS 20·6 (10·9–24·8) versus 19·0 (10·5–34·6) months, P = 0·811; DFS 6·6 (2·8–25·7) versus 9·3 (4·1–13·9) months, P = 0·191). Conclusion Patients who had oxaliplatin-based NACT showed a higher rate of chemoresistance to oxaliplatin at the time of CRS and HIPEC. The impact of chemosensitivity testing on OS remains unclear and needs further investigation." @default.
• W3155025544 created "2021-04-26" @default.
• W3155025544 creator A5009112103 @default.
• W3155025544 creator A5012076614 @default.
• W3155025544 creator A5022928632 @default.
• W3155025544 creator A5029814799 @default.
• W3155025544 creator A5042176709 @default.
• W3155025544 creator A5049886032 @default.
• W3155025544 creator A5063643956 @default.
• W3155025544 creator A5071812590 @default.
• W3155025544 creator A5077521077 @default.
• W3155025544 creator A5082392739 @default.
• W3155025544 creator A5088172222 @default.
• W3155025544 date "2021-03-01" @default.
• W3155025544 modified "2023-10-17" @default.
• W3155025544 title "Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study" @default.
• W3155025544 cites W189287319 @default.
• W3155025544 cites W1964736779 @default.
• W3155025544 cites W2004554342 @default.
• W3155025544 cites W2008342394 @default.
• W3155025544 cites W2012809050 @default.
• W3155025544 cites W2041574270 @default.
• W3155025544 cites W2042905608 @default.
• W3155025544 cites W2081482934 @default.
• W3155025544 cites W2096998881 @default.
• W3155025544 cites W2100446189 @default.
• W3155025544 cites W2101493293 @default.
• W3155025544 cites W2109794223 @default.
• W3155025544 cites W2116274195 @default.
• W3155025544 cites W2127015783 @default.
• W3155025544 cites W2142132573 @default.
• W3155025544 cites W2278968967 @default.
• W3155025544 cites W2347325034 @default.
• W3155025544 cites W2620543700 @default.
• W3155025544 cites W2779668451 @default.
• W3155025544 cites W2805520724 @default.
• W3155025544 cites W2810010855 @default.
• W3155025544 cites W2896899648 @default.
• W3155025544 cites W2904799830 @default.
• W3155025544 cites W2916344906 @default.
• W3155025544 cites W2921002193 @default.
• W3155025544 cites W2953997551 @default.
• W3155025544 cites W3012138955 @default.
• W3155025544 doi "https://doi.org/10.1093/bjsopen/zraa075" @default.
• W3155025544 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8038512" @default.
• W3155025544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33839755" @default.
• W3155025544 hasPublicationYear "2021" @default.
• W3155025544 type Work @default.
• W3155025544 sameAs 3155025544 @default.
• W3155025544 citedByCount "9" @default.
• W3155025544 countsByYear W31550255442022 @default.
• W3155025544 countsByYear W31550255442023 @default.
• W3155025544 crossrefType "journal-article" @default.
• W3155025544 hasAuthorship W3155025544A5009112103 @default.
• W3155025544 hasAuthorship W3155025544A5012076614 @default.
• W3155025544 hasAuthorship W3155025544A5022928632 @default.
• W3155025544 hasAuthorship W3155025544A5029814799 @default.
• W3155025544 hasAuthorship W3155025544A5042176709 @default.
• W3155025544 hasAuthorship W3155025544A5049886032 @default.
• W3155025544 hasAuthorship W3155025544A5063643956 @default.
• W3155025544 hasAuthorship W3155025544A5071812590 @default.
• W3155025544 hasAuthorship W3155025544A5077521077 @default.
• W3155025544 hasAuthorship W3155025544A5082392739 @default.
• W3155025544 hasAuthorship W3155025544A5088172222 @default.
• W3155025544 hasBestOaLocation W31550255441 @default.
• W3155025544 hasConcept C121608353 @default.
• W3155025544 hasConcept C126322002 @default.
• W3155025544 hasConcept C141071460 @default.
• W3155025544 hasConcept C143998085 @default.
• W3155025544 hasConcept C2776694085 @default.
• W3155025544 hasConcept C2779013556 @default.
• W3155025544 hasConcept C2779458272 @default.
• W3155025544 hasConcept C2780427987 @default.
• W3155025544 hasConcept C2780962732 @default.
• W3155025544 hasConcept C2781413609 @default.
• W3155025544 hasConcept C2994223192 @default.
• W3155025544 hasConcept C526805850 @default.
• W3155025544 hasConcept C71924100 @default.
• W3155025544 hasConcept C90924648 @default.
• W3155025544 hasConceptScore W3155025544C121608353 @default.
• W3155025544 hasConceptScore W3155025544C126322002 @default.
• W3155025544 hasConceptScore W3155025544C141071460 @default.
• W3155025544 hasConceptScore W3155025544C143998085 @default.
• W3155025544 hasConceptScore W3155025544C2776694085 @default.
• W3155025544 hasConceptScore W3155025544C2779013556 @default.
• W3155025544 hasConceptScore W3155025544C2779458272 @default.
• W3155025544 hasConceptScore W3155025544C2780427987 @default.
• W3155025544 hasConceptScore W3155025544C2780962732 @default.
• W3155025544 hasConceptScore W3155025544C2781413609 @default.
• W3155025544 hasConceptScore W3155025544C2994223192 @default.
• W3155025544 hasConceptScore W3155025544C526805850 @default.
• W3155025544 hasConceptScore W3155025544C71924100 @default.
• W3155025544 hasConceptScore W3155025544C90924648 @default.
• W3155025544 hasIssue "2" @default.
• W3155025544 hasLocation W31550255441 @default.
• W3155025544 hasLocation W31550255442 @default.
• W3155025544 hasOpenAccess W3155025544 @default.
• W3155025544 hasPrimaryLocation W31550255441 @default.
• W3155025544 hasRelatedWork W2163079911 @default.
• W3155025544 hasRelatedWork W2219306646 @default.

• next